Eur Respir J 2016; 48: 808–817 | DOI: 10.1183/13993003.00840-2016
Health and Human Rights Journal
December 2016 / Volume 18 / Number 2 / Papers, 171-182
Washington, D.C., ÉUA, du 26 au 30 septembre 2016
Point 4.10 de l’ordre du jour provisoire
CD55/14 8 juillet 2016
Original : anglais
Overview
Rev Panam Salud Publica 40(6), 2016
A long and healthy life for all South Africans
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
Document No. : FDA/SMC/SMD/GL-SMP/2015/05 |
These guidelines are for information, guidance and strict compliance by Marketing Authorization Holders and Local Representatives of regulated products to help in the continuous safety monitoring of products granted marketing authorization in Ghana.
Consolidated Guidelines
Geneva, 2016
The End TB Strategy
Issues in Educational Research, 26(1), 2016
The devastating impacts of the 2015–16 El Niño will be felt well into 2017. This crisis was predicted, yet overall, the response has been too little too late. The looming La Niña event may further hit communities that are already deeply vulnerable. To end this cycle of failure, there is an urgen...t need for humanitarian action where the situation is already dire, to prepare for La Niña later this year, to commit to comprehensive new measures to build communities’ resilience, and to mobilize global action to address climate change which is creating a ‘new normal’ of higher temperatures, drought and unpredictable growing seasons.
more
Standard Treatment Guideline
Systematic Review Summary 4
Irresponsible pharmaceutical companies fuel the proliferation of superbugs through supply chain pollution, the European Public Health Alliance (EPHA) reports. The advocacy group uncovered lapses such as dirty production and inadequate waste disposal in the production of antimicrobials in China and I...ndia, which supplies most of the antimicrobials consumed in Europe. In a briefing detailing the pollution, the EPHA urges major purchasers of antibiotics to blacklist irresponsible pharmaceutical companies, demand that the industry clean up its supply chain, introduce greater transparency on the origin of antibiotics, and review and revise procurement policies from an ethics perspective.
more